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Abstract
Background. The aim of the study was to investigate the lipid levels in patients with various physical activity and 
polymorphous variants of ADRB2 (Gln27Glu and Arg16Gly) and ADRB3 (Trp64Arg) genes.
Material and methods. One hundred and fifty subjects were enrolled in the study; mean age was 44.7 ± 8.9 y.o. 
Physical activity was assessed using Omron Walking style III step counter HJ-203-EK pedometer. Lipids were as-
sessed via enzymatic method using Cormay reagent kit (Poland). Genotyping of polymorphous sites of ADRB2 
(Gln27Glu, rs1042714 and Arg16Gly, rs1042713) and ADRB3 (Trp64Agr, rs4994) genes was performed using 
SNP-express-SHOT reagent kits manufactured by Litex Research and Production Company, via real-time polymer-
ase chain reaction.
Results. Individuals walking more than 5000 steps daily with Gly16Gly polymorphism had significantly higher 
blood lipids. Total cholesterol (TC), triglycerides, LDL and HDL-cholesterol levels were 5.10 (3.86–5.74), 1.13 
(0.66–1.51), 3.28 (2.14–3.70), 1.43 (1.32–1.63) mmol/L in Arg16 group and 5.55 (5.23–6.96), 1.56 (0.45– 
–2.02), 3.87 (3.09–4.46) and 1.30 (1.13–1.68) mmol/L in Gly16Gly group. The differences in lipid parameters 
were established for polymorphous variants of ADRB3 gene in patients walking more than 5000 steps daily. In 
Trp54 carriers, TC, triglycerides, LDL and HDL-cholesterol levels were 5.23 (4.00–5.69), 1.25 (0.80–1.56), 3.25 
(2.22–3.80) and 1.41 (1.26–1.53) mmol/L, respectively. In 54Arg carriers group, lipids were significantly higher: 
TC 5.74 (5.59–6.88), triglycerides 1.51 (1.03–1.90), LDL-cholesterol 3.78 (3.38–5.06) and HDL-cholesterol 
1.68 (1.13–1.81) mmol/L.
Conclusion. This analysis suggests that carriers of Arg16 of ADRB2 gene and/or Trp54 of ADRB3 gene tend to have 
lower lipid parameters when they have high physical activity (walking more than 5000 steps a day) in comparison to 
carriers of 16Gly and/or 54Agr. There is no association between lipids level and ADRB2 (Gln27Glu and Arg16Gly) 
and ADRB3 (Trp64Agr) polymorphisms when individuals have low physical activity (walking less than 5000 steps 
a day).
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Introduction
Dyslipidaemia is one of the main risk factors of car-
diovascular diseases. Polygenic dyslipidaemia along 
with hypertension and glucose metabolism distur-
bance is considered as a key compound of metabolic 
syndrome. European Society of Cardiology (ESC) 
and European Society of Hypertension (ESH) ex-
perts emphasize the necessity of dyslipidaemia treat-
ment and recommend physical activity as an integral 
part of lifestyle modification.
The onset and progression of polygenic dyslipi-
daemia is influenced by genetic susceptibility and 
environmental factors. Beta-2 and beta-3 adrener-
gic receptors play an important role in response to 
physical exercise, regulate lipid and carbohydrate me-
tabolism. Beta-2 and beta-3 adrenergic receptors are 
encoded by ADRB2 and ADRB3 genes, located on 
chromosomes 5 and 8, respectively [1].
Beta-2-adrenergic receptors are involved in fat 
mobilization from fatty cells for production of en-
ergy in response to stimulation via adrenaline and 
noradrenaline. The presence of amino acid substitu-
tions Gln27Glu and Arg16Gly results in formation 
of receptor less sensitive to the effect of agonists and 
causing less pronounced tissue response to stimula-
tion. Stimulation of beta-3-adrenergic receptors re-
sults in enhancement of lipolysis. Arg64 carriers have 
reduced lipolysis level. The presence of the above 
mutations can modify the body response to physical 
exercise.
Many candidate genes, polymorphisms of which 
are associated with the risk of development and se-
verity of dyslipidaemia, have been established. Be-
sides, polymorphous variants of the above genes are 
related to the body response to physical exercise. 
The best studied are the loci of the genes ADRB2 — 
rs1042714 (531 C>G, Gln27Glu) and rs1042713 
(46 A>G, Arg16Gly) and ADRB3 — rs4994 
(190T>C, Trp64Arg). According to literature data, 
different polymorphic forms of ADRB2 are associ-
ated with type 2 diabetes mellitus, obesity, nocturnal 
asthma, and decrease in arterial pressure (at rest, 
during, and after physical activity) [1]. Concurrently, 
individuals with genetic alterations in ADRB3 are 
characterized by lower energy expenditure and basal 
metabolic rate as compared to individuals without 
genetic alterations [2].
Physical activity is one of the main elements of 
lifestyle modification in prevention of lipid me-
tabolism disorders. Meta-analysis by Hanson and 
Jones showed that group walking promotes the de-
crease in total cholesterol [3]. The data presented 
by Mann et al. confirm the beneficial effects of 
regular activity on cholesterol levels and describe 
the impacts of different volumes and intensities 
of exercise on different types of cholesterol [4]. 
Prusik et al. revealed considerable effect of Nordic 
walking on lipid metabolism parameters in women 
[5]. Hagner-Derengowska et al., studying female 
population, also demonstrated statistically signifi-
cant effect of walking on blood lipid levels [6]. 
Williams and Thompson showed that walking and 
running decrease the risk of development of hyper-
cholesterolaemia in an equally effective manner [7]. 
The results by Marigliano et al. are in concordance 
with the data of the above discussed studies and 
demonstrate considerable positive effect of walking 
on lipid metabolism parameters [8]. At the same 
time, meta-analysis presented in 2018 by Oja et al. 
failed to demonstrate the direct effect of walking on 
cholesterol, while its essential effect on body mass 
index (BMI) and blood pressure parameters was 
proven [9]. An individual’s sensitivity to physical 
exercise as a factor regulating lipid metabolism can 
be predetermined genetically. That is why the goal 
of this study was to investigate lipid metabolism 
parameters associated with different physical activ-
ity levels in individuals with polymorphous variants 
of ADRB2 (Gln27Glu and Arg16Gly) and ADRB3 
(Trp64Arg) genes.
Material and methods
One hundred and fifty subjects were enrolled in 
the study; median age of the examined individu-
als was 44.2 [31.1–51.7] years. Thirty-five (23.3%) 
study subjects had essential hypertension. Patients 
with coronary heart disease, proven atherosclerotic 
lesions of coronary arteries, cardiac failure, patients 
administered with statins, having disorders of thy-
roid gland hormone-producing function, suffering 
from any diseases affecting mobility and physical 
activity, those on diets with strict limitations of any 
nutrients, having regular workouts, with body mass 
index greater than 40 kg/m2, and suffering from dia-
betes mellitus type 1 and 2 were not included into 
the study. Blood pressure-lowering therapy was car-
ried out with ramipril 5–10 mg daily and amlodipine 
5–10 mg daily.
Anthropometric parameters
Measurements of weight, height and waist circum-
ference were performed by trained physician. Body 
fat, visceral fat and muscular tissue percentage were 
obtained by bioelectrical impedance using OMRON 
(Tokyo, Japan) according to the manufacturer’s in-
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struction. Body mass index (BMI) was expressed 
as weight (kg) divided by squared height (meters) 
(BMI = kg/m2).
Physical activity
No additional intervention into the usual lifestyle of 
examined subjects was performed. The participants’ 
customary physical activity, in particular, walking, 
was assessed. Physical activity was assessed using 
Omron Walking style III step counter HJ-203-EK 
pedometer. The number of steps taken daily was re-
corded every day during the three consecutive days. 
Mean number of steps per day was calculated.
Biochemical tests
Venous blood samples were drawn from each subject 
after at least 10-h fasting period. Blood lipid spec-
trum — total cholesterol (TC), high density lipo-
protein cholesterol (HDL-cholesterol), triglycerides 
(TG) were determined via enzymatic method using 
Cormay reagent kit (Poland). The level of very low 
density lipoprotein cholesterol (VLDL-cholesterol) 
was calculated using the formula: 
VLDL-cholesterol = TG/5
The concentration of the LDL-cholesterol was 
calculated according to Friedwald’s formula, i.e.: the 
difference between total cholesterol and cholesterol 
concentrations in other lipoprotein fractions: 
LDL-cholesterol = TC – (TG/5+HDL-cholesterol)
Genotyping
Genotyping of polymorphous sites of ADRB2 (Gln-
27Glu, 531 C>G, rs1042714 and Arg16Gly, 46 
A>G, rs1042713) and ADRB3 (Trp64Agr, 190T>C, 
rs4994) genes was performed using reagent kits SNP-
express-SHOT manufactured by Litex Research and 
Production Company (Russian Federation), via real-
time polymerase chain reaction (PCR). DNA was 
isolated from whole blood using reagent kit DNA- 
-Sorb-B (Amplisense, Russian Federation).
Statistical analysis
The normality of variables’ distribution was assessed 
with Kolmogorov-Smirnov test. All data that con-
formed to normal distribution were expressed as 
means with SD. Otherwise, the data were presented 
as medians with corresponding quartiles (Q1; Q3). 
Statistical significance of differences between groups 
was assessed using Student’s t-test for samples meet-
ing normal distribution criteria, or Mann-Whitney 
test for samples not meeting normal distribution.
Results
Baseline characteristics of the study subjects divided 
into physical activity subgroups (less and more than 
5000 steps per day) are presented in Table I. The 
division point conformed to the mean number of 
Table I. Baseline characteristics of the study subgroups formed depending on daily physical activity
Variable All (n = 150) < 5000 steps per day 
(n = 86)
> 5000 steps per day 
(n = 64)
p-value
Age (years) 43.1 ± 11.2 44.1 ± 9.9 42.9 ± 11.1 0.52
Men/women 64/86 40/46 24/40 0.27
Anthropometrics
Weight [kg] 87.2 ± 23.5 83.5 ± 28.7 89.9 ± 25.0 0.17
BMI [kg/m2] 30.6 ± 7.3 31.1 ± 6.2 28.9 ± 8.3 0.35
Waist circumference 95.1 ± 17.1 92.0 ± 19.2 94.0 ± 13.0 0.47
Body fat (%) 38.0 ± 9.6 41.6 ± 7.4 38.0 ± 8.7 0.01
Muscle tissue (%) 27.2 ± 5.1 25.2 ± 4.0 26.1 ± 5.9 0.28
Visceral fat (%) 9.8 ± 4.7 9.2 ± 4.4 9.8 ± 4.1 0.40
Blood pressure
SBP [mm Hg] 139.1 ± 22.7 141.0 ± 21.7 137.2 ± 22.1 0.29
DBP [mm Hg] 84.4 ± 12.17 80.0 ± 12.4 82.8 ± 14.2 0.20
Lipids
Total cholesterol [mmol/L] 5.39 ± 0.97 5.53 ± 0.91 5.31 ± 1.07 0.18
Triglycerides [mmol/L] 1.54 ± 0.89 1.46 ± 0.92 1.43 ± 0.94 0.85
LDL-cholesterol [mmol/L] 3.39 ± 0.87 3.23 ± 0.91 3.39 ± 0.95 0.30
HDL-cholesterol [mmol/L] 1.39 ± 0.39 1.37 ± 0.39 1.53 ± 0.42 0.02
arterial hypertension 2018, vol. 22, no. 4
196 www.ah.viamedica.pl
Ta
bl
e 
II.
 B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
of
 th
e 
st
ud
y 
su
bj
ec
ts
 a
cc
or
di
ng
 to
 A
DR
B2
 a
nd
 A
DR
B3
 p
ol
ym
or
ph
is
m
s
Va
ria
bl
e
AD
RB
2 
(G
ln
27
Gl
)
p-
va
lu
e
AD
RB
2 
(A
rg
16
Gl
y)
p-
va
lu
e
AD
RB
3 
(T
rp
64
Ar
g)
p-
va
lu
e
CC
CG
+
GG
AA
+
AG
GG
TT
TC
N 
(%
)
87
 (5
8%
)
63
 (4
2%
)
53
 (3
5.
 3
%)
97
 (6
4.
7%
)
10
1 
(6
7.
3%
)
49
 (3
2.
6%
)
Ag
e
39
.7
 ±
 1
0.
2
41
.1
 ±
 9
.8
0.
40
43
.5
 ±
 1
3.
2
41
.6
 ±
 1
4.
4
0,
43
42
.1
 ±
 1
1.
3
44
.4
 ±
 1
1.
3
0.
3
An
th
ro
po
m
et
ric
s
W
eig
ht
 [k
g]
87
.5
 ±
 2
7.
9
87
.1
 ±
 2
1.
2
0.
92
85
.4
 ±
 2
4.
7
89
.9
 ±
 2
1.
5
0.
25
87
.5
 ±
 2
4.
5
86
.6
 ±
 1
9.
8
0.
82
BM
I, 
[k
g/
m
2]
30
.4
 ±
 8
.7
30
.7
 ±
 6
.5
0.
82
30
.4
 ±
 8
.1
31
.0
 ±
 6
.0
0.
61
31
.0
 ±
 7
.7
29
.3
 ±
 5
.3
0.
17
W
ais
t [
cm
]
94
.1
 ±
 1
8.
6
96
.2
 ±
 1
6.
4
0.
47
93
.9
 ±
 1
8.
6
97
.7
 ±
 1
4.
6
0.
18
95
.4
 ±
 1
7.
1
96
.6
 ±
 1
7.
2
0.
69
Bo
dy
 fa
t (
%)
37
.1
 ±
 8
.3
41
.3
 ±
 7
.2
0.
04
36
.2
 ±
 7
.1
39
.5
 ±
 8
.9
0.
02
38
.9
 ±
 9
.6
34
.6
 ±
 8
.7
0.
01
M
us
cle
 ti
ss
ue
 (%
)
27
.1
 ±
 5
.2
27
.3
8 
±
 5
.1
0.
75
27
.6
 ±
 5
.1
26
.7
 ±
 5
.4
0.
32
26
.7
 ±
 5
.1
29
.2
 ±
 4
.8
0.
01
Vi
sc
er
al 
fa
t (
%)
9.
3 
±
 4
.3
10
.1
4 
±
 4
.9
0.
25
9.
7 
±
 5
.3
10
.1
 ±
 3
.6
0.
58
9.
9 
±
 4
.8
9.
5 
±
 4
.1
0.
62
Bl
oo
d 
pr
es
su
re
SB
P 
[m
m
 H
g]
13
9.
5 
±
 2
1.
6
14
0.
2 
±
 3
2.
2
0.
87
14
1.
1 
±
 2
2.
7
13
8.
1 
±
 2
2.
6
0.
44
14
1.
2 
±
 2
1.
9
13
7.
0 
±
 2
3.
3
0.
28
DB
P 
[m
m
 H
g]
84
.1
 ±
 1
3.
1
84
.5
 ±
 1
2.
5
0.
85
84
.3
 ±
 1
3.
1
84
.6
 ±
 1
2.
1
0.
89
84
.4
 ±
 1
3.
1
85
.4
 ±
 1
0.
7
0.
64
Li
pi
ds
To
ta
l c
ho
les
te
ro
l [
m
m
ol/
l]
5.
30
 ±
 0
.7
9
5.
44
 ±
 1
.0
5
0.
35
5.
18
 ±
 0
.8
7
5.
29
 ±
 1
.0
3
0.
51
5.
29
 ±
 0
.9
8
5.
31
 ±
 0
.8
6
0.
90
Tr
ig
lyc
er
id
es
 [m
m
ol/
l]
1.
35
 ±
 0
.6
4
1.
33
 ±
 0
.9
8
0.
88
1.
43
 ±
 0
.9
0
1.
31
 ±
 0
.8
6
0.
42
1.
56
 ±
 0
.9
5
1.
48
 ±
 0
.6
9
0.
60
LD
L-
ch
ole
st
er
ol 
[m
m
ol/
l]
3.
34
 ±
 0
.6
2
3.
46
 ±
 0
.9
6
0.
11
3.
24
 ±
 0
.7
2
3.
39
 ±
 1
.0
1
0.
34
3.
27
 ±
 0
.8
5
3.
25
 ±
 0
.8
2
0.
89
HD
L-
ch
ole
st
er
ol 
[m
m
ol/
l]
1.
53
 ±
 0
.3
5
1.
49
 ±
 0
.4
0
0.
52
1.
40
 ±
 0
.3
6
1.
39
 ±
 0
.4
4
0.
89
1.
35
 ±
 0
.3
6
1.
41
 ±
 0
.4
9
0.
40
LD
L —
 lo
w
 d
en
sit
y 
lip
op
ro
te
in
; H
DL
 —
 h
ig
h 
de
ns
ity
 lip
op
ro
te
in
Anna Isayeva et al. Blood lipids level and physical activity
197www.ah.viamedica.pl
steps in the whole group (M ± SD, 5051 ± 1230 
steps per day). Groups with low and high physi-
cal activity (of less than 5000 and more than 5000 
steps a day, respectively) were comparable in terms of 
age, sex distribution, blood pressure parameters, and 
blood lipid parameters. Patients with lower physical 
activity had higher share of fatty tissue in the body 
(p = 0.04), although there were no significant differ-
ences between groups in BMI or shares of muscular 
tissue and visceral fat. No differences were found in 
total cholesterol, LDL-cholesterol and triglycerides 
between groups with high and low physical activity. 
Individuals with low physical activity had signifi-
cantly lower HDL-cholesterol (p = 0.02).
Several models were used for the comparison 
of polymorphous variants of each studied locus of 
ADRB2 and ADRB3 genes. Table II presents the 
characteristics of examined subjects depending on 
carriage of various alleles and genotypes of polymor-
phisms of studied genes. Analysis of models CC vs 
CG vs GG, CC+CG vs GG and C vs G of ADRB2 
gene revealed no significant differences in any of the 
tested parameters. In model CC vs CG+GG, sig-
nificantly higher fatty tissue content was identified 
in carriers of CG+GG (27Glu) genotypes.
Analysis of models AA vs AG vs GG, AA vs 
AA+AG, A vs G of ADRB2 gene (Arg16Gly) did not 
reveal significant differences between tested param-
eters as well. When the AA+AG vs GG model was 
used, significantly higher fatty tissue content was 
established in GG genotype carriers.
Analysis of parameters depending on polymor-
phous variants of ADRB3 gene established that in-
dividuals with TT genotype had higher fatty tissue 
share and lower muscular tissue share in the body. 
Body mass index showed no significant differences 
depending on the carriage of alleles and genotypes of 
polymorphous variants ADRB2 (Gln27Glu), ADRB2 
(Arg16Gly) and ADRB3 (Trp64Arg). Analysis of lip-
ids in subgroups depending on carriage of various 
polymorphous variants of tested loci failed to iden-
tify any significant differences as well.
The comparison of lipid metabolism parameters in 
carriers of various genotypes with relation to physi-
cal exercise is presented in Table III. No considerable 
differences in lipid levels were identified in the low 
physical exercise group during assessment of differ-
ent models.
We carried out a separate analysis of lipid levels 
in the group of study subjects walking more than 
5000 steps daily. Comparison of groups with differ-
ent genotypes of ADRB2 (Gln27Glu) polymorphism 
revealed no significant differences during analysis of 
CC vs CG vs GG, CC vs (CC+CG) and (CC+CG) 
vs GG models. Assessment of lipid parameters in 
patient groups with different genotypes of polymor-
Table III. Lipid metabolism parameters in groups with different genotypes of polymorphism of genes ADRB2 (Gln27Glu), ADRB2 (Arg16Gly), 
ADRB3 (Trp64Arg) in examined subjects with low daily physical activity expressed as < 5000 steps daily; n = 86
ADRB2 (Gln27Glu) p-value
CC (n = 39) CG + GG (n = 47)
Total cholesterol [mmol/L] 5.41 [4.88–6.22] 5.70 [5.21–6.18] 0.13
Triglycerides [mmol/L] 1.49 [1.02–2.34] 1.46 [0.89–2.55] 0.75
LDL-cholesterol [mmol/L] 2.92 [2.79–3.50] 3.40 [2.02–4.58] 0.15
HDL-cholesterol [mmol/L] 1.40 [1.14–1.65] 1.41 [1.00–1.78] 0.18
ADRB2 (Arg16Gly) p-value
AA + AG (n = 7) GG (n = 59)
Total cholesterol [mmol/L] 5.34 [4.74–5.51] 5.37 [4.73–6.65] 0.22
Triglycerides [mmol/L] 1.28 [0.83–1.84] 1.33 [1.03–1.90] 0.12
LDL-cholesterol [mmol/L] 3.22 [2.81–3.77] 3,78[2,43–4,82] 0.48
HDL-cholesterol [mmol/L] 1.37 [1.14–1.53] 1.30 [0.98–1.55] 0.36
ADRB3 (Trp64Arg) p-value
TT (n = 64) TC (n = 22)
Total cholesterol [mmol/L] 5.37 [4.69–6.01] 5.35 [5.32–6.59] 0.47
Triglycerides [mmol/L] 1.35 [0.74–1.27] 1.41 [0.81–1.70] 0.23
LDL-cholesterol [mmol/L] 3.17 [2.58–3.69] 3.15 [2.23–4.12] 0.44
HDL-cholesterol [mmol/L] 1.39 [1.07–1.54] 1.28 [1.16–1.40] 0.46
LDL — low density lipoprotein; HDL — high density lipoprotein
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phism of ADRB2 (Arg16Gly) gene demonstrated 
that carriers of GG genotype had higher levels of to-
tal cholesterol, LDL-cholesterol and HDL-cholester-
ol, as well as triglycerides, in the high physical activ-
ity group compared to carriers of AA+AG genotypes. 
Lipid parameters also differed depending on ADRB3 
(Trp64Arg) polymorphous variants. TC genotype 
carriers had significantly higher total cholesterol and 
LDL-cholesterol levels (Table IV).
Discussion
Our study showed the association between polymor-
phous variants of ADRB2 (Gln27Glu and Arg16Gly) 
and ADRB3 (Trp64Arg) and blood lipids level. This 
association was significant only if individuals have 
high daily physical activity. Significantly higher total 
cholesterol levels were identified in carriers of homo-
zygous genotype GG of gene ADRB2 (Arg16Gly) 
polymorphism and carriers of minor allele C of gene 
ADRB3 (Trp64Arg) polymorphism only in a group 
of patients with higher physical activity.
The obtained results do not allow stating the as-
sociation of polymorphous variants ADRB2 (Gln-
27Glu), ADRB2 (Arg16Gly), ADRB3 (Trp64Arg) 
with cholesterol level in the whole population of 
examined subjects, while in higher physical activ-
ity, association between genetic polymorphisms and 
lipid metabolism parameters becomes statistically 
significant.
The above mentioned polymorphous variants are 
rather widely studied as genetic markers of the risk 
of obesity, diabetes mellitus, and diet intervention 
sensitivity disorders [10–13]. Polymorphous locus 
Trp64Arg of ADRB3 gene was studied in many 
works [12, 14–16]. Trp64Arg polymorphism de-
creases sensitivity of beta-3-adrenergic receptor [17, 
18]. Gene ADRB2 encoding lipolytic receptor in 
human fatty cells, hepatocytes, muscular cells, asso-
ciated with lipid mobilization, lipolysis. Arg16Gly 
and Gln27Glu polymorphisms are deemed the best 
studied as risk markers of obesity and diabetes mel-
litus. Change of amino acid sequence on extracel-
lular N-end of ADRB2 in carriers of minor alleles 
of polymorphisms rs1042713 and rs1042714 can 
result in ADRB2 dysfunction. Literature describes 
quite many studies demonstrating the relation be-
tween ADRB2 (Gln27Glu), ADRB2 (Arg16Gly) 
polymorphisms and risk of development, as well 
as severity of the course of obesity and diabetes 
mellitus. At the same time, beta-2-adrenergic re-
ceptor also plays a role in cholesterol metabolism 
regulation [19]. The work by Tomaszewski et al. 
established the association of ADRB2 (Gln27Glu), 
ADRB2 (Arg16Gly) polymorphisms with cho-
Table IV. Lipid metabolism parameters in groups with different genotypes of polymorphism of ADRB2 (Gln27Glu), ADRB2 (Arg6Gly), 
ADRB3 (Trp64Arg) genes in examined subjects with high daily physical activity expressed as > 5000 steps daily; (n = 64)
ADRB2 (Gln27Glu) p-value
CC + CG (n = 48) GG (n = 16)
Total cholesterol [mmol/L] 5.33 [4.00–6.14] 5.31 [5.23–5.55] 0.84
Triglycerides [mmol/L] 1.13 [0.88–1.51] 2.33 [1.36–3.56] 0.01
LDL-cholesterol [mmol/L] 3.63 [3.20–4.43] 3.09 [2.21–3.78] 0.34
HDL-cholesterol [mmol/L] 1.43 [1.30–1.68] 1.13 [1.03–1.53] 0.35
ADRB2 (Arg16Gly)
AA + AG (n = 26) GG (n = 22)
Total cholesterol [mmol/L] 5.10 [3.86–5.74] 5.55 [5.23–6.96] 0.03
Triglycerides [mmol/L] 1.13 [0.66–1.51] 1.56 [0.45–2.02] 0.07
LDL-cholesterol [mmol/L] 3.28 [2.14–3.70] 3.87 [3.09–4.46] 0.05
HDL-cholesterol [mmol/L] 1.43 [1.32–1.63] 1.30 [1.13–1.68] 0.55
ADRB3 (Trp64Arg)
TT (n = 37) TC (n = 27)
Total cholesterol [mmol/L] 5.23 [4.00–5.69] 5.74 [5.59–6.88] 0.006
Triglycerides [mmol/L] 1.25 [0.80–1.56] 1.51 [1.03–1.90] 0.22
LDL-cholesterol [mmol/L] 3.25 [2.22–3.80] 3.78 [3.38–5.06] 0.057
HDL-cholesterol [mmol/L] 1.41 [1.26–1.53] 1.68 [1.13–1.81] 0.30
LDL — low density lipoprotein; HDL — high density lipoprotein
Anna Isayeva et al. Blood lipids level and physical activity
199www.ah.viamedica.pl
lesterol levels for Polish patient population with 
essential hypertension [20]. The authors showed 
that coexistence of Arg16 allele and Gln27 allele at 
the ADRB2 locus showed a borderline association 
with the increased risk of elevated LDL. Moreover, 
Arg16–Gln27 ADRB2 configuration, detrimental 
genotype at neuropeptide Y Leu7Pro doubled the 
risk of elevated LDL in hypertensive subjects [20]. 
The fact that these polymorphisms can modulate 
the lipid metabolism response to external interven-
tions, e.g. dietary ones, is rather interesting. Thus, 
Ramos-Lopez et al. demonstrated that the decrease 
in lipid levels in response to dietary interventions 
would be different in carriers of different genotypes 
of ADRB2 (Gln27Glu) and ADRB2 (Arg16Gly) 
polymorphisms [21]. They studied the effects of 
two types of dietary interventions (moderately high 
protein program and low fat program) on cholester-
ol level decrease depending on carriage of ADRB2 
(Gln27Glu) and (Arg16Gly) polymorphisms. It 
should be mentioned that baseline levels of total 
cholesterol and its fractions did not differ between 
carriers of different polymorphous gene variants. 
However, carriers of Gly16Gly genotype ADRB2 
(GG) showed less pronounced decrease in total cho-
lesterol and LDL-cholesterol levels when prescribed 
with moderately high protein program versus the 
carriers of Arg16 allele (AA+AG). When prescribed 
with low fat diet, Gly16Gly and Arg16 carriers 
demonstrated comparable decrease in lipid levels 
[21]. The study by Ramos-Lopez et al. confirms the 
fact that polymorphous sites ADRB2 (Gln27Glu) 
and ADRB2 (Arg16Gly), certainly, do not prede-
termine the lipid level in general population, but 
can modulate the response to environmental effects, 
which in this case was dietary intervention [21].
The role of mutations in ADRB3 gene is also 
extensively studied. Results of several studies enable 
concluding that Trp64Arg (19T>C) polymorphism 
ADRB3 is associated with abnormal function of beta-
3 adrenergic receptor in the fat tissue [14, 22, 23]. 
The work by Brondani et al. showed that C allele 
(64Arg) of ADRB3 gene was associated with protec-
tive effect against obesity. Besides, this work estab-
lished that carriers of C allele (64Arg) had higher 
level of HDL-cholesterol [22]. The study by Chen et 
al. demonstrated that, in Chinese population, carri-
ers of Trp64Trp genotype of ADRB3 gene had higher 
triglyceride levels [17]. Our study did reveal the as-
sociation of TT (Trp64Trp) genotype with higher 
triglyceride level, which can be explained by inter-
ethnic differences.
The goal of our study was not the investigation 
of relation between the presented polymorphisms 
and presence of obesity. At the same time, it was 
established that, although there were no significant 
differences in BMI between groups with different 
genotypes of polymorphisms of adrenergic receptor 
genes, carriers of allele A (AA+AG) genotypes of 
ADRB2 (Arg16) gene and TT genotype of ADRB3 
(Trp64Trp) gene had higher fatty tissue share.
This study did not establish the relation between 
genotypes of ADRB2 (Gln27Glu) polymorphism 
and lipid level either in general population of ex-
amined subjects or in subgroups with low and high 
physical activity. At the same time, analysis of lipid 
parameters in patient groups with different geno-
types of polymorphism of ADRB2 gene (Arg16Gly) 
demonstrated that carriers of homozygous GG geno-
type (Gly16Gly) with higher physical activity had 
considerably higher parameters of total cholesterol, 
triglycerides, and LDL-cholesterol compared to the 
group of (AA+AG) genotype carriers, which means 
that these individuals were less sensitive to physical 
exercise as a factor affecting the lipid level. The sec-
ond group less sensitive to physical exercise as a fac-
tor affecting the lipid metabolism is represented by 
carriers of minor allele C of 19T > C polymorphism 
(rs4994, Trp64Arg) of ADRB3 gene. Thus, the ob-
tained data demonstrate the role of polymorphism 
carriage in formation of body response to physical 
exercise. The study conducted by Leońska-Duniec 
et al. in Polish population also revealed that the 
response to physical exercise differed depending on 
carriage of polymorphous variants. Unlike our work, 
the authors analysed the results of active interven-
tion into patients’ lifestyle. It was established dur-
ing a 12-week aerobic training program that carriers 
of minor alleles Gly16 and Glu27 of ADRB2 gene 
demonstrated more pronounced decrease in fatty tis-
sue share [24]. Probably, during lifestyle correction, 
these patients should take into account their lower 
sensitivity to aerobic physical exercise. This study has 
several limitations. The work was conducted in a lim-
ited population, n=150. Although the physical activ-
ity assessment was carried out for several days, only 
one activity type, walking, was taken into account.
Conclusion
Carriers of Arg16 (AA+AG) of ADRB2 gene and TT 
(Trp54) of ADRB3 gene have lower lipid parameters 
under the conditions of equal physical exercise. As-
sociation with polymorphous variants of these genes 
is manifested only in the case of physical exercise 
exceeding 5000 steps daily.
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